| Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis DA Rossignol, RE Frye Molecular psychiatry 17 (3), 290-314, 2012 | 899 | 2012 |
| A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and … DA Rossignol, RE Frye Molecular psychiatry 17 (4), 389-401, 2012 | 642 | 2012 |
| Melatonin in autism spectrum disorders: a systematic review and meta‐analysis DA Rossignol, RE Frye Developmental Medicine & Child Neurology 53 (9), 783-792, 2011 | 575 | 2011 |
| Environmental toxicants and autism spectrum disorders: a systematic review DA Rossignol, SJ Genuis, RE Frye Translational psychiatry 4 (2), e360-e360, 2014 | 524 | 2014 |
| Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism DA Rossignol, RE Frye Frontiers in physiology 5, 76429, 2014 | 358 | 2014 |
| Cerebral folate receptor autoantibodies in autism spectrum disorder RE Frye, JM Sequeira, EV Quadros, SJ James, DA Rossignol Molecular psychiatry 18 (3), 369-381, 2013 | 288 | 2013 |
| Novel and emerging treatments for autism spectrum disorders: a systematic review DA Rossignol Ann Clin Psychiatry 21 (4), 213-236, 2009 | 268 | 2009 |
| Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders RE Frye, DA Rossignol Pediatric research 69 (8), 41-47, 2011 | 252 | 2011 |
| Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder S Rose, DM Niyazov, DA Rossignol, M Goldenthal, SG Kahler, RE Frye Molecular diagnosis & therapy 22, 571-593, 2018 | 195 | 2018 |
| The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study DA Rossignol, LW Rossignol, SJ James, S Melnyk, E Mumper BMC pediatrics 7, 1-13, 2007 | 172 | 2007 |
| Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial DA Rossignol, LW Rossignol, S Smith, C Schneider, S Logerquist, ... BMC pediatrics 9, 1-15, 2009 | 162 | 2009 |
| Emerging biomarkers in autism spectrum disorder: a systematic review RE Frye, S Vassall, G Kaur, C Lewis, M Karim, D Rossignol Annals of translational medicine 7 (23), 2019 | 140 | 2019 |
| Evidence of mitochondrial dysfunction in autism and implications for treatment DA Rossignol, JJ Bradstreet American Journal of Biochemistry and Biotechnology 4 (2), 208-217, 2008 | 132 | 2008 |
| A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel RE Frye, D Rossignol, MF Casanova, GL Brown, V Martin, S Edelson, ... Frontiers in public health 1, 31, 2013 | 120 | 2013 |
| Hyperbaric oxygen therapy may improve symptoms in autistic children DA Rossignol, LW Rossignol Medical hypotheses 67 (2), 216-228, 2006 | 107 | 2006 |
| Melatonin in autism spectrum disorders DA Rossignol, RE Frye Current clinical pharmacology 9 (4), 326-334, 2014 | 106 | 2014 |
| Identification and treatment of pathophysiological comorbidities of autism spectrum disorder to achieve optimal outcomes RE Frye, DA Rossignol Clinical Medicine Insights: Pediatrics 10, CMPed. S38337, 2016 | 104 | 2016 |
| Treatments for biomedical abnormalities associated with autism spectrum disorder RE Frye, DA Rossignol Frontiers in pediatrics 2, 66, 2014 | 90 | 2014 |
| Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder JJ Bradstreet, S Smith, M Baral, DA Rossignol Altern Med Rev 15 (1), 15-32, 2010 | 89 | 2010 |
| The use of medications approved for Alzheimer’s disease in autism spectrum disorder: a systematic review DA Rossignol, RE Frye Frontiers in pediatrics 2, 87, 2014 | 88 | 2014 |
Richard E FryeRossignol Medical CenterVerified email at rossignolmedicalcenter.com
